Expression and Clinical Significance of TIGIT in Primary Breast Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen international consensus guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216–1235. doi:10.1016/j.annonc.2021.06.023
   PubMed Web of Science ®Google Scholar
• Kashyap D, Pal D, Sharma R, et al. Global increase in breast cancer incidence: risk factors and preventive measures. Biomed Res Int. 2022;2022:9605439. doi:10.1155/2022/9605439
   PubMed Web of Science ®Google Scholar
• Zhang J, Da M, Yuan M, et al. Prevention and treatment measures related to peripheral neuropathy caused by paclitaxel-based chemotherapy drugs in breast cancer patients. Adv Clin Exp Med. 2022;12(7):6377–6383. doi:10.12677/ACM.2022.127919
   Google Scholar
• Yeo J, Ko M, Lee DH, Park Y, Jin HS. TIGIT/CD226 Axis regulates anti-tumor immunity. Pharmaceuticals. 2021;14(3):200. doi:10.3390/ph14030200
   Web of Science ®Google Scholar
• Mocellin S, Benna C, Pilati P. Coinhibitory molecules in cancer biology and therapy. Cytokine Growth Factor Rev. 2013;24(2):147–161. doi:10.1016/j.cytogfr.2013.01.003
   PubMed Web of Science ®Google Scholar
• Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 2012;24(2):213–216. doi:10.1016/j.coi.2011.12.005
   PubMed Web of Science ®Google Scholar
• Nair S, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells, by Varun Sasidharan Nair and Eyad Elkord (Erratum). Immunol Cell Biol. 2018;96(2):236. doi:10.1111/imcb.12012
   PubMed Web of Science ®Google Scholar
• Tunger A, Kießler M, Wehner R, et al. Immune monitoring of cancer patients prior to and during CTLA-4 or PD-1/PD-L1 inhibitor treatment. Biomedicines. 2018;6(1):1. doi:10.3390/biomedicines6010026
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Fishman MN, Escudier B, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin Cancer Res. 2016;22(22):5461–5471. doi:10.1158/1078-0432.Ccr-15-2839
   PubMed Web of Science ®Google Scholar
• Huang R, Cui Y, Guo Y. Programmed cell death protein-1 predicts the recurrence of breast cancer in patients subjected to radiotherapy after breast-preserving surgery. Technol Cancer Res Treat. 2018;17:1533033818793425. doi:10.1177/1533033818793425
   Web of Science ®Google Scholar
• Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86. doi:10.3389/fonc.2018.00086
   PubMed Web of Science ®Google Scholar
• Dixon KO, Schorer M, Nevin J, et al. Functional Anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol. 2018;200(8):3000–3007. doi:10.4049/jimmunol.1700407
   PubMed Web of Science ®Google Scholar
• Gardiner D, Lalezari J, Lawitz E, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One. 2013;8(5):e63818. doi:10.1371/journal.pone.0063818
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015;15(1):45–56. doi:10.1038/nri3790
   PubMed Web of Science ®Google Scholar
• Sarhan D, Cichocki F, Zhang B, et al. Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells. Cancer Res. 2016;76(19):5696–5706. doi:10.1158/0008-5472.Can-16-0839
   PubMed Web of Science ®Google Scholar
• Kurtulus S, Sakuishi K, Ngiow SF, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125(11):4053–4062. doi:10.1172/jci81187
   PubMed Web of Science ®Google Scholar
• Chew GM, Fujita T, Webb GM, et al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV Infection. PLoS Pathog. 2016;12(1):e1005349. doi:10.1371/journal.ppat.1005349
   PubMed Web of Science ®Google Scholar
• Gil Del Alcazar CR, Huh SJ, Ekram MB, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 2017;7(10):1098–1115. doi:10.1158/2159-8290.Cd-17-0222
   PubMed Web of Science ®Google Scholar
• Cari L, Nocentini G, Migliorati G, Riccardi C. Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: a bioinformatics analysis. Oncoimmunology. 2018;7(2):e1387705. doi:10.1080/2162402x.2017.1387705
   PubMed Web of Science ®Google Scholar
• Yuan L, Yuan P, Yuan H, et al. miR-542-3p inhibits colorectal cancer cell proliferation, migration and invasion by targeting OTUB1. Am J Cancer Res. 2017;7(1):159–172.
   PubMed Web of Science ®Google Scholar
• Mahoney MC, Bevers T, Linos E, Willett WC. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin. 2008;58(6):347–371. doi:10.3322/ca.2008.0016
   PubMed Web of Science ®Google Scholar
• Pauken KE, Wherry EJ. TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit. Cancer Cell. 2014;26(6):785–787. doi:10.1016/j.ccell.2014.11.016
   PubMed Web of Science ®Google Scholar
• Li X, Wang R, Fan P, et al. A comprehensive analysis of key immune checkpoint receptors on tumor-infiltrating T cells from multiple types of cancer. Front Oncol. 2019;9:1066. doi:10.3389/fonc.2019.01066
   PubMed Web of Science ®Google Scholar
• He W, Zhang H, Han F, et al. CD155T/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res. 2017;77(22):6375–6388. doi:10.1158/0008-5472.Can-17-0381
   PubMed Web of Science ®Google Scholar
• Tang W, Pan X, Han D, et al. Clinical significance of CD8(+) T cell immunoreceptor with Ig and ITIM domains(+) in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy. Oncoimmunology. 2019;8(6):e1593807. doi:10.1080/2162402x.2019.1593807
   PubMed Web of Science ®Google Scholar
• Bi J, Zheng X, Chen Y, Wei H, Sun R, Tian Z. TIGIT safeguards liver regeneration through regulating natural killer cell-hepatocyte crosstalk. Hepatology. 2014;60(4):1389–1398. doi:10.1002/hep.27245
   PubMed Web of Science ®Google Scholar
• Fang J, Chen F, Liu D, Gu F, Chen Z, Wang Y. Prognostic value of immune checkpoint molecules in breast cancer. Biosci Rep. 2020;40(7):Jul. doi:10.1042/bsr20201054
   Google Scholar
• Zhang X, Zhang H, Chen L, Feng Z, Gao L, Li Q. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia. Cell Immunol. 2019;344:103958. doi:10.1016/j.cellimm.2019.103958
   PubMed Web of Science ®Google Scholar
• Wu J. Clinical significance of recurrence and metastasis index in patients with differentiated thyroid carcinoma and related risk factors. Pract J Cancer. 2017;32(4):606–608.
   Google Scholar
• Konat-Bąska K, Matkowski R, Błaszczyk J, et al. Does breast cancer increasingly affect younger women? Int J Environ Res Public Health. 2020;17(13):4884. doi:10.3390/ijerph17134884
   PubMed Web of Science ®Google Scholar
• Li W, Blessin NC, Simon R, et al. Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma. BMC Cancer. 2018;18(1):1209. doi:10.1186/s12885-018-5111-1
   PubMedGoogle Scholar
• Im SJ, Hashimoto M, Gerner MY, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417–421. doi:10.1038/nature19330
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–732. doi:10.1038/s41590-018-0132-0
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang Y, Xun X, et al. TIGIT can exert immunosuppressive effects on CD8+ T Cells by the CD155/TIGIT signaling pathway for hepatocellular carcinoma in vitro. J Immunother. 2020;43(8):236–243. doi:10.1097/cji.0000000000000330
   PubMed Web of Science ®Google Scholar
• Liu XG, Hou M, Liu Y. TIGIT, A novel therapeutic target for tumor immunotherapy. Immunol Invest. 2017;46(2):172–182. doi:10.1080/08820139.2016.1237524
   PubMed Web of Science ®Google Scholar
• Xu F, Sunderland A, Zhou Y, Schulick RD, Edil BH, Zhu Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol Immunother. 2017;66(10):1367–1375. doi:10.1007/s00262-017-2031-x
   PubMed Web of Science ®Google Scholar
• Chan IS, Knútsdóttir H, Ramakrishnan G, et al. Cancer cells educate natural killer cells to a metastasis-promoting cell state. J Cell Biol. 2020;219(9):Sep. doi:10.1083/jcb.202001134
   Web of Science ®Google Scholar
• Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957. doi:10.1136/jitc-2020-000957
   PubMed Web of Science ®Google Scholar
• Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12:699895. doi:10.3389/fimmu.2021.699895
   PubMed Web of Science ®Google Scholar